Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Antivascular endothelial growth factor (anti-VEGF) drugs used for ophthalmic conditions account for more than $6 billion in Part B Medicare costs.1 Recent research2,3 has shown that bevacizumab may be equally as effective as the more-expensive agents (aflibercept and ranibizumab) for some but not all retinal vascular diseases. Using provider-level billing data for Medicare beneficiaries, we analyzed geographic trends in anti-VEGF therapy to identify whether the use of lower-cost drugs increased among ophthalmologists from calendar years 2012 to 2013.
Thakore RV, Greenberg PB, Behrens JJ, French DD. Variation in Ophthalmologist Use of Antivascular Endothelial Growth Factor Therapy Among Medicare Beneficiaries. JAMA Ophthalmol. 2016;134(9):1071-1072. doi:10.1001/jamaophthalmol.2016.2051